Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 18 01 2021
accepted: 06 05 2021
entrez: 4 6 2021
pubmed: 5 6 2021
medline: 30 9 2021
Statut: epublish

Résumé

Monomethyl fumarate (MMF), metabolite of dimethyl fumarate (DMF), an immunosuppressive drug approved for the treatment of multiple sclerosis (MS), is a potent agonist for hydroxycarboxylic acid receptor 2 (HCAR2), eliciting signals that dampen cell activation or lead to inflammation such as the skin flushing reaction that is one of the main side effects of the treatment, together with gastrointestinal inflammation. Our aim is to further understand the molecular basis underlying these differential effects of the drug. We have used wild-type and HCAR2 knock-out mice to investigate,

Identifiants

pubmed: 34084164
doi: 10.3389/fimmu.2021.655212
pmc: PMC8167049
doi:

Substances chimiques

Biomarkers 0
Fumarates 0
Hcar2 protein, mouse 0
Immunosuppressive Agents 0
Receptors, G-Protein-Coupled 0
monomethyl fumarate 45IUB1PX8R
Mapk1 protein, mouse EC 2.7.11.24
Mapk3 protein, mouse EC 2.7.11.24
Mitogen-Activated Protein Kinase 1 EC 2.7.11.24
Mitogen-Activated Protein Kinase 3 EC 2.7.11.24

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

655212

Informations de copyright

Copyright © 2021 Parodi, Sanna, Cedola, Uccelli and Kerlero de Rosbo.

Déclaration de conflit d'intérêts

AU has received consulting honoraria including as part of advisory board and/or speaker fees from Sanofi Genzyme, Roche, Biogen, Novartis, TEVA and Merck. This work was supported in part by a Basic Science Study grant from Biogen to AU. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Clin Pharmacol Drug Dev. 2017 Nov;6(6):604-613
pubmed: 28783872
J Vis Exp. 2012 May 21;(63):e4040
pubmed: 22644046
Front Immunol. 2015 Jun 02;6:254
pubmed: 26082775
Brain. 2018 Jul 1;141(7):1900-1916
pubmed: 29860380
Gut. 2016 Feb;65(2):256-70
pubmed: 25666191
J Biol Chem. 1998 Apr 3;273(14):8017-24
pubmed: 9525901
J Exp Med. 2007 Aug 6;204(8):1757-64
pubmed: 17620361
J Exp Med. 2005 Oct 17;202(8):1063-73
pubmed: 16216890
J Biol Chem. 2012 Aug 10;287(33):28017-26
pubmed: 22733812
J Clin Invest. 2009 Sep;119(9):2441-50
pubmed: 19729841
J Clin Invest. 2010 Aug;120(8):2910-9
pubmed: 20664170
J Clin Invest. 2014 May;124(5):2188-92
pubmed: 24691444
Pharmacol Rev. 2011 Jun;63(2):269-90
pubmed: 21454438
Clin Ther. 2013 Oct;35(10):1582-1594.e9
pubmed: 24139424
Adv Struct Chem Imaging. 2017;3(1):4
pubmed: 28261542
Gastroenterology. 1988 May;94(5 Pt 1):1164-71
pubmed: 3350286
J Synchrotron Radiat. 2017 Nov 01;24(Pt 6):1226-1236
pubmed: 29091066
Gastroenterology. 2011 Nov;141(5):1802-12
pubmed: 21723222
Science. 2005 Mar 25;307(5717):1920-5
pubmed: 15790845
Int J Clin Exp Pathol. 2015 Nov 01;8(11):14649-57
pubmed: 26823788
Clin Cancer Res. 2003 May;9(5):1885-97
pubmed: 12738747
Front Immunol. 2017 Sep 14;8:1096
pubmed: 28959254
Eur J Immunol. 1995 Jul;25(7):1951-9
pubmed: 7621871
J Biol Chem. 2007 Sep 21;282(38):27622-32
pubmed: 17635918
Nature. 1994 Nov 10;372(6502):190-3
pubmed: 7969453
Mol Pharmacol. 2018 Apr;93(4):259-265
pubmed: 29326242
Gut. 2010 May;59(5):595-604
pubmed: 20427394
J Clin Invest. 2009 May;119(5):1312-21
pubmed: 19349687
Nat Rev Immunol. 2008 May;8(5):362-71
pubmed: 18379575
Front Immunol. 2017 Dec 22;8:1922
pubmed: 29312359
J Clin Invest. 1994 Jul;94(1):202-9
pubmed: 8040262
Immunity. 2004 Oct;21(4):527-38
pubmed: 15485630
J Exp Med. 2005 Oct 17;202(8):1051-61
pubmed: 16216886
J Crohns Colitis. 2016 Apr;10(4):472-83
pubmed: 26690241
Opt Express. 2010 Mar 29;18(7):6423-36
pubmed: 20389666
J Clin Invest. 2005 Dec;115(12):3634-40
pubmed: 16322797
J Crohns Colitis. 2008 Dec;2(4):352-6
pubmed: 21172238
Pharmacol Rev. 2019 Apr;71(2):267-315
pubmed: 30914442
Annu Rev Biochem. 2000;69:145-82
pubmed: 10966456
J Pharmacol Exp Ther. 2011 May;337(2):391-9
pubmed: 21310817
J Exp Med. 2009 Dec 21;206(13):3101-14
pubmed: 20008524
FASEB J. 2013 Nov;27(11):4366-74
pubmed: 23882124
Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18169-74
pubmed: 17978190
J Immunol. 2006 May 1;176(9):5205-12
pubmed: 16621985
Cell Death Dis. 2014 May 15;5:e1228
pubmed: 24832600
Gastroenterology. 2011 Nov;141(5):1821-31
pubmed: 22027263
Phys Med Biol. 2013 Jan 7;58(1):R1-35
pubmed: 23220766
Mucosal Immunol. 2009 Jul;2(4):340-50
pubmed: 19387433
PLoS One. 2014 Sep 03;9(9):e106335
pubmed: 25184418
Neurotherapeutics. 2018 Jan;15(1):68-74
pubmed: 29119385
Acta Neuropathol. 2015 Aug;130(2):279-95
pubmed: 25920452
Mol Pharmacol. 1994 Sep;46(3):460-9
pubmed: 7935326
Eur J Immunol. 2010 Jul;40(7):1877-83
pubmed: 20432234
Sci Rep. 2017 Jul 19;7(1):5890
pubmed: 28724999
Cell Death Differ. 2015 Feb;22(2):215-24
pubmed: 25168240
Cancer Res. 2009 Apr 1;69(7):2826-32
pubmed: 19276343
J Exp Med. 2011 Oct 24;208(11):2291-303
pubmed: 21987655
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17384-9
pubmed: 21960443
Cell Death Differ. 2008 Jan;15(1):134-42
pubmed: 17932499
J Immunol. 2012 Dec 15;189(12):5745-54
pubmed: 23152564
Eur J Immunol. 2009 Aug;39(8):2215-23
pubmed: 19655301
Gut. 2009 Nov;58(11):1481-9
pubmed: 19570762
Brain. 2011 Mar;134(Pt 3):678-92
pubmed: 21354971
Trends Immunol. 2011 Sep;32(9):412-9
pubmed: 21816673
Eur J Immunol. 2004 Feb;34(2):565-75
pubmed: 14768062
Nat Commun. 2016 Feb 24;7:10842
pubmed: 26905976
N Engl J Med. 2012 Sep 20;367(12):1087-97
pubmed: 22992072
Immunity. 2005 Apr;22(4):493-505
pubmed: 15845453
Mult Scler Relat Disord. 2014 Jul;3(4):513-9
pubmed: 25877064
Neurol Neuroimmunol Neuroinflamm. 2016 Oct 12;3(6):e291
pubmed: 27766282
Adv Ther. 2019 Nov;36(11):3154-3165
pubmed: 31538304
J Eur Acad Dermatol Venereol. 2018 Oct;32 Suppl 3:3-14
pubmed: 30238510
Immunity. 2014 Jan 16;40(1):128-39
pubmed: 24412617
J Leukoc Biol. 2017 Feb;101(2):377-394
pubmed: 27899415
J Pathol. 2003 Jan;199(1):98-106
pubmed: 12474232
Exp Dermatol. 2018 Jun;27(6):611-624
pubmed: 29603404
J Immunol. 2006 Jan 15;176(2):803-10
pubmed: 16393963

Auteurs

Benedetta Parodi (B)

Neuroimmunology Laboratory, DINOGMI, University of Genoa, Genoa, Italy.

Alessia Sanna (A)

CNR-Institute of Nanotechnology, Rome, Italy.

Alessia Cedola (A)

CNR-Institute of Nanotechnology, Rome, Italy.

Antonio Uccelli (A)

Neuroimmunology Laboratory, DINOGMI, University of Genoa, Genoa, Italy.
IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Nicole Kerlero de Rosbo (N)

Neuroimmunology Laboratory, DINOGMI, University of Genoa, Genoa, Italy.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
C-Reactive Protein Humans Biomarkers Inflammation
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH